HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Givaudan S&E

This article was originally published in The Rose Sheet

Executive Summary

Fragrance revenues advanced 5.7% in local currencies and 8% in Swiss francs to $728.4 mil. (CH1=$0.79) for the first nine months of the year, Givaudan reports Oct. 6. Fine fragrance continued double-digit growth in all regions, "essentially driven by new wins and a low erosion rate of the existing product portfolio," firm notes. Givaudan's net sales for the period increased 3.3% in local currencies and 5.5% in Swiss francs to $1.75 bil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel